We are live on
!
Find out more
State Street SPDR S&P Pharmaceuticals ETF
XPH
XPH
60 hedge funds and large institutions have $156M invested in State Street SPDR S&P Pharmaceuticals ETF in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
15% less funds holding
Funds holding: 71 → 60 (-11)
20.57% less ownership
Funds ownership: 52.65% → 32.08% (-21%)
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
40% less capital invested
Capital invested by funds: $259M → $156M (-$104M)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Holders
60
Holders Change
-11
Holders Change %
-15.49%
% of All Funds
1.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
18
Reduced
23
Closed
13
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
+$4K
Top Buyers
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$82.9M |
| 2 |
Barclays
London,
United Kingdom
|
-$19M |
| 3 |
Morgan Stanley
New York
|
-$4.85M |
| 4 |
SG Americas Securities
New York
|
-$4.11M |
| 5 |
Citigroup
New York
|
-$2.13M |
